• Align Technology announced that long-serving Chairman C. Raymond Larkin, Jr. will retire as Chairman effective July 1, 2026, with independent director Kevin Conroy set to assume the role while Larkin remains on the Board through December 31, 2026 to support the transition.
• This change brings in a new Chair with recent experience leading a multi-billion-dollar healthcare company through commercialization and acquisition, potentially influencing Align’s governance and long-term priorities.
• With Kevin Conroy’s healthcare leadership background now central to Align’s boardroom, we’ll assess how this leadership shift affects its investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Align Technology Investment Narrative Recap

To own Align today, you need to believe clear aligners and digital dentistry can support steady growth despite pricing pressure, macro headwinds, and rising competition. The key near term catalyst remains execution on product innovation and doctor utilization, while the biggest risk is ongoing discounting and mix shift toward lower priced cases. The planned handover from long-time Chair C. Raymond Larkin Jr. to Kevin Conroy looks orderly and does not materially change those near term drivers or risks.

The most relevant recent update alongside this chair transition is Align’s Q1 2026 earnings, where management reaffirmed its 2026 guidance for modest revenue growth and slightly sub 18% GAAP operating margins. That backdrop matters, because the board shift comes as Align is working to defend margins against discounting and mix pressure, while still investing in its digital platform and manufacturing footprint, all of which feed directly into the catalysts investors are watching.

Yet while the leadership transition may support Align’s story, investors should also understand how sensitive that story is to sustained discounting and mix shifts...

Align Technology's narrative projects $4.7 billion revenue and $726.5 million earnings by 2029. This requires 4.9% yearly revenue growth and a $316.1 million earnings increase from $410.4 million today.

Uncover how Align Technology's forecasts yield a $201.69 fair value, a 11% upside to its current price.

Exploring Other Perspectives

The lowest analyst estimates paint a more cautious picture than consensus, even before this chair change, with revenue modeled at about US$4.5 billion and earnings around US$675.8 million by 2029. These pessimists see execution risk as higher and pricing power as weaker than the base case, so if you are following Align you should compare how that view on margins and growth might shift as the new chair and board priorities become clearer.

Explore 6 other fair value estimates on Align Technology - why the stock might be worth as much as 56% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Align Technology research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Align Technology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Align Technology's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.